Viral Vectors in Cancer Immunotherapy

Viral Vectors in Cancer Immunotherapy, Volume 379, discusses advances in immune checkpoint inhibitors and adoptive cell therapy, including the use of genetically modified viruses to express pro-inflammatory molecules and induce tumor cell death.

Format: Hardback
Length: 277 pages
Publication date: 01 August 2023
Publisher: Elsevier Science Publishing Co Inc

The use of genetically modified viruses in cancer immunotherapy has revolutionized the field of cancer treatment, offering new hope for patients with various types of malignancies. In Volume 379 of the International Review of Cell and Molecular Biology, experts in the field present the latest advancements in cancer immunotherapy, highlighting the transformative impact of immune checkpoint inhibitors and adoptive cell therapy.

Chapters in this comprehensive release delve into the past, present, and future of viral vectors in cancer immunotherapy. The authors explore the role of alphaviruses, adenoviruses, and other viral vectors in delivering therapeutic genes to cancer cells, promoting immune responses, and ultimately achieving tumor regression.

The book also discusses the use of armored modified vaccinia Ankara (MVA) in cancer immunotherapy, which has shown promising results in treating solid tumors. MVA is a modified vaccinia virus that has been engineered to express tumor-specific antigens and induce immune responses against cancer cells.

Strategies of Semliki Forest virus in immuno-oncology are explored, highlighting its potential as an oncolytic virus in the treatment of hematological malignancies. Semliki Forest virus has been shown to selectively kill cancer cells while sparing normal cells, making it an attractive option for cancer therapy.

Maraba virus in cancer immunotherapy is discussed, exploring its ability to trigger immune responses and induce tumor cell death. Maraba virus has shown promising results in treating acute myeloid leukemia (AML) and other blood cancers.

The book also provides an overview of oncolytic viruses in hematological malignancies, including herpes simplex virus (HSV) and Newcastle disease virus (NDV). Oncolytic viruses have been used as therapeutic agents to kill cancer cells, and their effectiveness is being studied in clinical trials.

Furthermore, the book explores the use of oncolytic viruses for cancer therapies: Overview and future directions. The authors discuss the potential benefits and challenges of using oncolytic viruses as cancer treatments, as well as the ongoing research and development efforts in this field.

Viral vectors in cancer immunotherapy have opened up new avenues for personalized medicine, allowing doctors to tailor treatment plans to individual patients' needs. The use of genetically modified viruses allows the expression of pro-inflammatory molecules, which can help stimulate the immune system to attack cancer cells. In some cases, the virus can also induce tumor cell death, offering a potential alternative to conventional chemotherapy and radiation therapy.

This book is a valuable resource for researchers, physicians, and healthcare professionals interested in the latest developments in cancer immunotherapy. It provides a comprehensive overview of viral vectors, their applications in cancer therapy, and the potential for future breakthroughs in this field. With its extensive coverage and expert insights, Viral Vectors in Cancer Immunotherapy, Volume 379 is a must-read for anyone seeking to stay informed about the latest advancements in cancer treatment.

Weight: 450g
Dimension: 229 x 151 (mm)
ISBN-13: 9780443192494